[1] Wang CW, Li YY, Zhu SG, et al. Surgical management and evaluation of prognostic factors influencing postoperative visual outcome of suprasellar meningiomas. World Neurosurg. 2011. 75(2): 294-302.
[2] Komotar RJ, Starke RM, Raper DM, Anand VK, Schwartz TH. Endoscopic endonasal versus open transcranial resection of anterior midline skull base meningiomas. World Neurosurg. 2012. 77(5-6): 713-24.
[3] Ajlan AM, Choudhri O, Hwang P, Harsh G. Meningiomas of the tuberculum and diaphragma sellae. J Neurol Surg B Skull Base. 2015. 76(1): 74-9.
[4] Nanda A, Ambekar S, Javalkar V, Sharma M. Technical nuances in the management of tuberculum sellae and diaphragma sellae meningiomas. Neurosurg Focus. 2013. 35(6): E7.
[5] Shen CC, Wang YC, Hua WS, Chang CS, Sun MH. Endoscopic endonasal transsphenoidal surgery for pituitary tumors. Zhonghua Yi Xue Za Zhi (Taipei). 2000. 63(4): 301-10.
[6] Cappabianca P, Cirillo S, Alfieri A, et al. Pituitary macroadenoma and diaphragma sellae meningioma: differential diagnosis on MRI. Neuroradiology. 1999. 41(1): 22-6.
[7] Kwancharoen R, Blitz AM, Tavares F, Caturegli P, Gallia GL, Salvatori R. Clinical features of sellar and suprasellar meningiomas. Pituitary. 2014. 17(4): 342-8.
[8] Donovan JL, Nesbit GM. Distinction of masses involving the sella and suprasellar space: specificity of imaging features. AJR Am J Roentgenol. 1996. 167(3): 597-603.
[9] Singhal T. Positron emission tomography applications in clinical neurology. Semin Neurol. 2012. 32(4): 421-31.
[10] Xiangsong Z, Xinjian W, Yong Z, Weian C. 13N-NH3: a selective contrast-enhancing tracer for brain tumor. Nucl Med Commun. 2008. 29(12): 1052-8.
[11] Xiangsong Z, Weian C, Dianchao Y, Xiaoyan W, Zhifeng C, Xiongchong S. Usefulness of (13)N-NH (3) PET in the evaluation of brain lesions that are hypometabolic on (18)F-FDG PET. J Neurooncol. 2011. 105(1): 103-7.
[12] Shi X, Liu Y, Zhang X, et al. The comparison of 13N-ammonia and 18F-FDG in the evaluation of untreated gliomas. Clin Nucl Med. 2013. 38(7): 522-6.
[13] Shi X, Yi C, Wang X, et al. 13N-ammonia combined with 18F-FDG could discriminate between necrotic high-grade gliomas and brain abscess. Clin Nucl Med. 2015. 40(3): 195-9.
[14] Xiangsong Z, Xingchong S, Chang Y, Xiaoyan W, Zhifeng C. 13N-NH3 versus F-18 FDG in detection of intracranial meningioma: initial report. Clin Nucl Med. 2011. 36(11): 1003-6.
[15] Yamamoto H, Konno H, Yamamoto T, Ito K, Mizugaki M, Iwasaki Y. Glutamine synthetase of the human brain: purification and characterization. J Neurochem. 1987. 49(2): 603-9.
[16] Zaidi HA, Cote DJ, Castlen JP, et al. Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression. World Neurosurg. 2017. 97: 2-7.
[17] Castlen JP, Cote DJ, Zaidi HA, Laws ER Jr. The extended, transnasal, transsphenoidal approach for anterior skull base meningioma: considerations in patient selection. Pituitary. 2017. 20(5): 561-568.
[18] Kawamata T, Iseki H, Shibasaki T, Hori T. Endoscopic augmented reality navigation system for endonasal transsphenoidal surgery to treat pituitary tumors: technical note. Neurosurgery. 2002. 50(6): 1393-7.
[19] Koutourousiou M, Fernandez-Miranda JC, Wang EW, Snyderman CH, Gardner PA. Endoscopic endonasal surgery for olfactory groove meningiomas: outcomes and limitations in 50 patients. Neurosurg Focus. 2014. 37(4): E8.
[20] Morales-Valero SF, Van Gompel JJ, Loumiotis I, Lanzino G. Craniotomy for anterior cranial fossa meningiomas: historical overview. Neurosurg Focus. 2014. 36(4): E14.
[21] Al-Mefty O, Holoubi A, Rifai A, Fox JL. Microsurgical removal of suprasellar meningiomas. Neurosurgery. 1985. 16(3): 364-72.
[22] Kim YH, Wang KC, Phi JH, Kim SK. Endoscopic Endonasal Approach for Suprasellar Lesions in Children: Complications and Prevention. J Korean Neurosurg Soc. 2017. 60(3): 315-321.
[23] Koutourousiou M, Fernandez-Miranda JC, Stefko ST, Wang EW, Snyderman CH, Gardner PA. Endoscopic endonasal surgery for suprasellar meningiomas: experience with 75 patients. J Neurosurg. 2014. 120(6): 1326-39.
[24] Turel MK, Tsermoulas G, Reddy D, Andrade-Barazarte H, Zadeh G, Gentili F. Endonasal endoscopic transsphenoidal excision of tuberculum sellae meningiomas: a systematic review. J Neurosurg Sci. 2016. 60(4): 463-75.
[25] Hershey BL. Suprasellar masses: diagnosis and differential diagnosis. Semin Ultrasound CT MR. 1993. 14(3): 215-31.
[26] Sahin N, Melhem ER, Wang S, et al. Advanced MR imaging techniques in the evaluation of nonenhancing gliomas: perfusion-weighted imaging compared with proton magnetic resonance spectroscopy and tumor grade. Neuroradiol J. 2013. 26(5): 531-41.
[27] Direksunthorn T, Chawalparit O, Sangruchi T, et al. Diagnostic performance of perfusion MRI in differentiating low-grade and high-grade gliomas: advanced MRI in glioma, A Siriraj project. J Med Assoc Thai. 2013. 96(9): 1183-90.
[28] Filss CP, Galldiks N, Stoffels G, et al. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors. J Nucl Med. 2014. 55(4): 540-5.
[29] Rossi Espagnet MC, Romano A, Mancuso V, et al. Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET. Br J Radiol. 2016. 89(1066): 20160476.
[30] Zhao S, Kuge Y, Mochizuki T, et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med. 2005. 46(4): 675-82.
[31] Filss CP, Cicone F, Shah NJ, Galldiks N, Langen KJ. Amino acid PET and MR perfusion imaging in brain tumours. Clin Transl Imaging. 2017. 5(3): 209-223.
[32] Xiangsong Z, Weian C. Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET. J Neurooncol. 2007. 82(3): 305-11.
[33] Shi X, Zhang X, Yi C, Wang X, Chen Z, Zhang B. The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients. Clin Nucl Med. 2013. 38(2): 98-102.
[34] Bergström M, Muhr C, Lundberg PO, Långström B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med. 1991. 32(4): 610-5.
[35] Hyun SH, Choi JY, Lee KH, Choe YS, Kim BT. Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria. J Nucl Med. 2011. 52(4): 547-50.
[36] De Souza B, Brunetti A, Fulham MJ, et al. Pituitary microadenomas: a PET study. Radiology. 1990. 177(1): 39-44.
[37] Ju H, Zhou J, Pan Y, Lv J, Zhang Y. Evaluation of pituitary uptake incidentally identified on 18F-FDG PET/CT scan. Oncotarget. 2017. 8(33): 55544-55549.
[38] Cooper AJ. 13N as a tracer for studying glutamate metabolism. Neurochem Int. 2011. 59(4): 456-64.
[39] Boksha IS, Tereshkina EB, Burbaeva GS. Glutamine synthetase and glutamine synthetase-like protein from human brain: purification and comparative characterization. J Neurochem. 2000. 75(6): 2574-82.
[40] Ott P, Larsen FS. Blood-brain barrier permeability to ammonia in liver failure: a critical reappraisal. Neurochem Int. 2004. 44(4): 185-98.
[41] Phelps ME, Hoffman EJ, Coleman RE, et al. Tomographic images of blood pool and perfusion in brain and heart. J Nucl Med. 1976. 17(7): 603-12.
[42] Phelps ME, Huang SC, Hoffman EJ, Selin C, Kuhl DE. Cerebral extraction of N-13 ammonia: its dependence on cerebral blood flow and capillary permeability -- surface area product. Stroke. 1981. 12(5): 607-19.
[43] DeBerardinis RJ, Cheng T. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010. 29(3): 313-24.
[44] He Q, Shi X, Zhang L, Yi C, Zhang X, Zhang X. De Novo Glutamine Synthesis: Importance for the Proliferation of Glioma Cells and Potentials for Its Detection With 13N-Ammonia. Mol Imaging. 2016. 15.
[45] Shi X, Zhang X, Yi C, Liu Y, He Q. [¹³N]Ammonia positron emission tomographic/computed tomographic imaging targeting glutamine synthetase expression in prostate cancer. Mol Imaging. 2014. 13.
[46] McCormick D, McQuaid S, McCusker C, Allen IV. A study of glutamine synthetase in normal human brain and intracranial tumours. Neuropathol Appl Neurobiol. 1990. 16(3): 205-11.
[47] Spampinato MV, Smith JK, Kwock L, et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol. 2007. 188(1): 204-12.
[48] Kung HN, Marks JR, Chi JT. Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia. PLoS Genet. 2011. 7(8): e1002229.
[49] Labow BI, Souba WW, Abcouwer SF. Mechanisms governing the expression of the enzymes of glutamine metabolism--glutaminase and glutamine synthetase. J Nutr. 2001. 131(9 Suppl): 2467S-74S; discussion 2486S-7S.
[50] Shirasawa N, Yamanouchi H. Glucocorticoids induce glutamine synthetase in folliculostellate cells of rat pituitary glands in vivo and in vitro. J Anat. 1999. 194 ( Pt 4): 567-77.
[51] Xiangsong Z, Dianchao Y, Anwu T. Dynamic 13N-ammonia PET: a new imaging method to diagnose hypopituitarism. J Nucl Med. 2005. 46(1): 44-7.